Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 preclinical gene therapy for polycystic kidney disease (600K US patients) using AI-driven target identification; $1.1M raised with NIH SBIR grant, raising $4M seed competing with CRISPR Therapeutics for curative kidney genetic medicine.
Nephrogen is a San Francisco-based preclinical gene therapy company — backed by Y Combinator (W20) with $1.1 million in total funding including $775,000 raised to date plus a $325,000 NIH SBIR grant, and currently raising a $4 million seed round with support from StartX and 2048 Ventures — developing curative gene therapies for kidney diseases, with polycystic kidney disease (PKD) as the lead program targeting the 600,000 Americans with the autosomal dominant PKD subtype, an inherited kidney cyst disorder with no disease-modifying treatments that currently progresses to end-stage renal disease requiring dialysis or transplant in the majority of patients. Founded by researchers with combined expertise in AI-driven drug discovery, genetic engineering, and nephrology, Nephrogen applies AI target identification and gene therapy delivery to the largest category of rare inherited kidney diseases.
Autonomous mobile robot company for warehouse automation; flexible AMR-based fulfillment systems that adapt to changing product mixes without fixed infrastructure.
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and manufacturing facilities. The company builds ground-based autonomous robots capable of transporting goods, fulfilling orders, and navigating dynamic warehouse environments alongside human workers, with software for fleet management and warehouse orchestration.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.